课题基金 / 基金详情

MODULATION OF HOST CELL APOPTOTIC RESPONSES BY HPVE7

MODULATION OF HOST CELL APOPTOTIC RESPONSES BY HPVE7
HPVE7 对宿主细胞凋亡反应的调节
批准号:
7917800
负责人:
Karl Munger
金额:
$30.13万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-02-15 至 2014-12-31
关键词:
AerobicAffectAnusApoptosisApoptoticAutophagocytosisBiologicalBiological AssayCancer EtiologyCarcinomaCaspaseCell Cycle ArrestCell DeathCell ProliferationCellsCervix carcinomaCessation of lifeChromosomesClinicCommitConflict (Psychology)Death RateEpithelial CellsEquilibriumEventFermentationFibroblastsGenomeGenomicsGleevecGlycolysis InhibitionGrowthGrowth FactorHPV-High RiskHumanHuman Papilloma Virus VaccineHuman PapillomavirusHuman papillomavirus 16IncidenceInfectionLeadLesionLife Cycle StagesMalignant - descriptorMalignant Epithelial CellMalignant NeoplasmsMalignant neoplasm of cervix uteriMalignant neoplasm of penisMediatingMetabolicMetabolic stressModalityMolecularMutationNormal CellNormal tissue morphologyOncogene ActivationOncogene ProteinsOncogenesOncogenicPDZ proteinPathway interactionsPhiladelphiaPhosphotransferasesPremalignantProtein BindingPublicationsRelative (related person)ReportingSentinelSerumSignal TransductionSignal Transduction PathwaySolid NeoplasmTP53 geneTertiary Protein StructureTestingTherapeuticTumor Suppressor ProteinsVaccinationVaccinesViralViral ProteinsVulvaWarburg EffectWomanWorkaddictionbasecarcinogenesiscell suicidecellular targetingdefense responsedeprivationdetection of nutrientexperiencefollow-uphuman FRAP1 proteininhibitor/antagonistkeratinocytekinase inhibitorleukemiamTOR InhibitormTOR inhibitionmalignant mouth neoplasmmortalitynovel therapeuticsprophylacticprotein expressionprotein protein interactionpublic health relevanceresearch studyresponsesenescencesensorsmall moleculetissue culturetumor progression

项目摘要

项目成果

Karl Munger的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): High-risk human papillomaviruses (HPVs) are etiological agents of cervical cancer, the second most common cause of cancer death in women worldwide. In addition, high-risk HPVs are also associated with a number of other anogenital tract carcinomas, including, anal, vulvar and penile cancers as well as approximately 20% of oral cancers. Despite the recent introduction of a prophylactic vaccine that is to protect from infection with some high-risk HPV types, it will be several decades before this will affect cervical cancer incidence and death rates. Currently 10 women succumb to cervical cancer every day in the US, alone. HPV-associated carcinogenesis is driven by HPV E6/E7 oncoprotein expression; these proteins not only contribute to induction of premalignant lesions, but also mechanistically contribute to malignant progression, a relatively rare event that generally occurs several years to decades after the initial infection. Progression is frequently associated with HPV genome integration into a host cellular chromosome, a terminal event for the viral life cycle. As a consequence, E6 and E7 are the only viral proteins that are consistently expressed in cervical cancers. This project is focused on investigating biological activities of high-risk HPV oncoproteins and to determine whether they could be harnessed as a novel therapeutic modality for high-risk HPV-associated lesions and cancers. In aim 1, it is proposed to determine the mechanistic basis of HPV16 E7-induced trophic sentinel signaling in human keratinocytes, a cellular tumor suppressor pathway that thwarts the proliferation of cells that have suffered oncogenic alterations, which lead to aberrant cell proliferation. Aim 2 is to determine the mechanistic basis of HPV16 E7-induced autophagy in human keratinocytes and if/how this is connected to trophic sentinel signaling. Since autophagy is an evolutionary ancient and conserved response to metabolic stress we will determine how HPV16 E7 expression causes increased metabolic requirements. Aim 3 is to investigate the mechanism by which HPV16 E6 abrogates HPV16 E7 induced trophic sentinel signaling. In this aim we will test whether small molecule inhibitors of the pathways that E6 and E7 may be targeting and that are currently in the clinic may be harnessed as a novel therapeutic modality for HPV-associated lesions and cancers. Since the cellular pathways that are targeted by the E6 and E7 oncoproteins are frequently rendered dysfunctional by mutation in non-HPV associated human solid tumors, these studies may also be applicable for therapy of other human cancers. PUBLIC HEALTH RELEVANCE: Infections with high-risk human papillomaviruses (HPVs) have been associated with variety human cancers, including cervical carcinoma, the second most common cause of cancer death in women worldwide. Despite the recent introduction of a prophylactic HPV vaccine, it will be decades before such vaccination will decrease incidence and mortality of cervical cancer and more than 10 women will succumb to HPV-associated cervical cancer in the US every day for the next several decades. The focus of this proposal is to determine the molecular mechanisms by which HPV16 E7 oncoprotein expression predisposes cells to commit cellular suicide, to delineate the mechanism by which the E6 oncoprotein holds this E7 activity in check and to perform proof of principle experiments with small molecule inhibitors that are already in the clinic to determine whether this dormant cell death response may be harnessed as a therapeutic modality for HPV-associated lesions and cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of the Human Papillomavirus Life Cycle by the Long Noncoding RNA DINO
  • 批准号:
    10743142
  • 项目类别:
  • 资助金额:
    $41.84万
  • 财政年份:
    2023
  • 负责人:
    Karl Munger
  • 依托单位:
Mechanistic studies on the unique set of accessory proteins encoded by the gamma 6 human papillomaviruses
  • 批准号:
    10495249
  • 项目类别:
  • 资助金额:
    $20.24万
  • 财政年份:
    2021
  • 负责人:
    Karl Munger
  • 依托单位:
Mechanistic studies on the unique set of accessory proteins encoded by the gamma 6 human papillomaviruses
  • 批准号:
    10349083
  • 项目类别:
  • 资助金额:
    $24.36万
  • 财政年份:
    2021
  • 负责人:
    Karl Munger
  • 依托单位:
NHLBI Short-Term Training Program Increase Diversity in Health-Related Research
  • 批准号:
    7619109
  • 项目类别:
  • 资助金额:
    $9.68万
  • 财政年份:
    2007
  • 负责人:
    Karl Munger
  • 依托单位:
海外基金